ORYZF (Oryzon Genomics) Research & Development: $10.16 Mil (TTM As of Mar. 2026)


ORYZF Oryzon Genomics SA ORYZF
31 GF Score
Price $3.65
View Full Analysis

What is Oryzon Genomics Research & Development?

Oryzon Genomics ORYZF 31 Research & Development is $10.16 Mil as of Mar. 2026. GuruFocus rates ORYZF with a GF Score™ of 31/100.

Research & Development is the aggregate amount of research and development expenses during the year. Oryzon Genomics's Research & Development for the three months ended in Mar. 2026 was $5.17 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $10.16 Mil.

Oryzon Genomics  (OTCPK:ORYZF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Oryzon Genomics Research & Development Related Terms

Oryzon Genomics Research & Development Historical Data

* Premium members only.

The historical data trend for Oryzon Genomics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oryzon Genomics Research & Development Chart

Oryzon Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Oryzon Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.58 1.14 3.86 0.00 5.17
ORYZF
31GF Score
Oryzon Genomics SA ORYZF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $10.16 Mil mean?
Oryzon Genomics (ORYZF) has a Research & Development of $10.16 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Oryzon Genomics and its competitors.
Is Oryzon Genomics' Research & Development too high?
Oryzon Genomics' current Research & Development is $10.16 Mil. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Research & Development compare to VRTX and REGN?
Oryzon Genomics' Research & Development of $10.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Oryzon Genomics and its competitors. Oryzon Genomics's current Research & Development is $10.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (ORYZF) has a current Research & Development of $10.16 Mil. The current Research & Development is $10.16 Mil. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Oryzon Genomics (ORYZF), the current Research & Development is $10.16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Other Exchanges 0RDB:UKORY:SpainORN:Germany
Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score

Get the complete analysis for ORYZF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.65
Price